These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 14714044)

  • 1. [A role for antipsychotic agents in the membrane hypothesis of schizophrenia?].
    Skrede S; Holmsen H
    Tidsskr Nor Laegeforen; 2003 Sep; 123(18):2568-70. PubMed ID: 14714044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Schizophrenia: diverse approaches to a complex disease.
    Sawa A; Snyder SH
    Science; 2002 Apr; 296(5568):692-5. PubMed ID: 11976442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of phospholipases A2 in schizophrenia.
    Law MH; Cotton RG; Berger GE
    Mol Psychiatry; 2006 Jun; 11(6):547-56. PubMed ID: 16585943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glutamate agonist activity: implications for antipsychotic drug action and schizophrenia.
    Banerjee SP; Zuck LG; Yablonsky-Alter E; Lidsky TI
    Neuroreport; 1995 Dec; 6(18):2500-4. PubMed ID: 8741750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurodevelopmental Animal Models Reveal the Convergent Role of Neurotransmitter Systems, Inflammation, and Oxidative Stress as Biomarkers of Schizophrenia: Implications for Novel Drug Development.
    Möller M; Swanepoel T; Harvey BH
    ACS Chem Neurosci; 2015 Jul; 6(7):987-1016. PubMed ID: 25794269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuropathology markers and pathways associated with molecular targets for antipsychotic drugs in postmortem brain tissues: exploration of drug targets through the Stanley Neuropathology Integrative Database.
    Kim S; Zavitsanou K; Gurguis G; Webster MJ
    Eur Neuropsychopharmacol; 2012 Oct; 22(10):683-94. PubMed ID: 22356822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholinergic aspects of schizophrenia.
    Tandon R
    Br J Psychiatry Suppl; 1999; (37):7-11. PubMed ID: 10211133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging as tool to investigate psychoses and antipsychotics.
    Booij J; van Amelsvoort T
    Handb Exp Pharmacol; 2012; (212):299-337. PubMed ID: 23129337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Membrane fatty acid levels as a predictor of treatment response in chronic schizophrenia.
    Sumiyoshi T; Higuchi Y; Matsui M; Itoh H; Uehara T; Itoh T; Arai H; Takamiya C; Suzuki M; Kurachi M
    Psychiatry Res; 2011 Mar; 186(1):23-7. PubMed ID: 20800904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroactive steroids in schizophrenia.
    Shulman Y; Tibbo PG
    Can J Psychiatry; 2005 Oct; 50(11):695-702. PubMed ID: 16363462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokine hypothesis of schizophrenia pathogenesis: evidence from human studies and animal models.
    Watanabe Y; Someya T; Nawa H
    Psychiatry Clin Neurosci; 2010 Jun; 64(3):217-30. PubMed ID: 20602722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha7 nicotinic cholinergic neuromodulation may reconcile multiple neurotransmitter hypotheses of schizophrenia.
    Bencherif M; Stachowiak MK; Kucinski AJ; Lippiello PM
    Med Hypotheses; 2012 May; 78(5):594-600. PubMed ID: 22336089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Receptor polymorphism and response to treatment in schizophrenia].
    Szekeres G; Janka Z
    Orv Hetil; 2002 Sep; 143(35):2027-33. PubMed ID: 12387196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Schizophrenia drug discovery and development in an evolving era: are new drug targets fulfilling expectations?
    Dunlop J; Brandon NJ
    J Psychopharmacol; 2015 Feb; 29(2):230-8. PubMed ID: 25586401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.
    Miyamoto S; Duncan GE; Marx CE; Lieberman JA
    Mol Psychiatry; 2005 Jan; 10(1):79-104. PubMed ID: 15289815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrating the neurobiology of schizophrenia. Preface.
    Abi-Dargham A; Guillin O
    Int Rev Neurobiol; 2007; 78():xiii-xvi. PubMed ID: 17349855
    [No Abstract]   [Full Text] [Related]  

  • 17. Neurotensin-dopamine interactions: relevance to schizophrenia and the action of antipsychotic drugs.
    Stowe ZN; Bissette G; Nemeroff CB
    Yakubutsu Seishin Kodo; 1991 Feb; 11(1):49-59. PubMed ID: 1679273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabotropic glutamate receptor 5 in schizophrenia: emerging evidence for the development of antipsychotic drugs.
    Newell KA
    Future Med Chem; 2013 Sep; 5(13):1471-4. PubMed ID: 24024939
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research.
    Arranz MJ; de Leon J
    Mol Psychiatry; 2007 Aug; 12(8):707-47. PubMed ID: 17549063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of antipsychotic treatment on membrane phospholipid metabolism in schizophrenia.
    Schmitt A; Maras A; Petroianu G; Braus DF; Scheuer L; Gattaz WF
    J Neural Transm (Vienna); 2001; 108(8-9):1081-91. PubMed ID: 11716143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.